Using ctDNA & Immune Biomarkers to Capture Dynamic Tumor Biology, Monitor Treatment Response, & Guide Smarter Vaccine Design
Time: 2:00 pm
day: Conference Day One
Details:
• Using ctDNA as a biomarker to monitor treatment response
• Harnessing ctDNA to fine-tune vaccine design based on evolving tumor profiles for reducing clinical failure
• Using biomarker signatures like CD80, PD-L1, and CD4/CD8 ratios to assess immunogenic potential and stratify patients most likely to benefit from PCVs
• Translating dynamic tumor insights into actionable design pivots to optimize a durable response
